Pcn89 - Cost –Effectiveness Analysis of Pertuzumab as First Line Neoadjuvant Treatment Option for Patients Her2 + Breast Cancer in Republic of Macedonia

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.171

Related search